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Abstract The aim of obtaining novel vaccine candidates
against malaria and other transmissible diseases can be
partly based on selecting non-polymorphic peptides from
relevant antigens of pathogens, which have to be then
precisely modified for inducing a protective immunity
against the disease. Bearing in mind the high degree of the
MSA-221–40 peptide primary structure’s genetic conserva-
tion among malaria species, and its crucial role in the high
RBC binding ability of Plasmodium falciparum (the main
agent causing malaria), structurally defined probes based
on non-natural peptide-bond isosteres were thus designed.
Thus, two peptide mimetics were obtained (so-called
reduced amide pseudopeptides), in which naturally made
amide bonds of the 30FIN32-binding motif of MSA-2 were
replaced with w–[CH2–NH] methylene amide isostere
bonds, one between the F–I and the second between I–N
amino acid pairs, respectively, coded as w-128 w-130.
These peptide mimetics were used to produce poly- and
monoclonal antibodies in Aotus monkeys and BALB/c
mice. Parent reactive mice-derived IgM isotype cell clones
were induced to Ig isotype switching to IgG sub-classes by
controlled in vitro immunization experiments. These
mature isotype immunoglobulins revealed a novel epitope
in the MSA-225–32 antigen and two polypeptides of rodent
malaria species. Also, these antibodies’ functional activity
against malaria was tested by in vitro assays, demonstrating
high efficacy in controlling infection and evidencing neu-
tralizing capacity for the rodent in vivo malaria infection.
The neutralizing effect of antibodies induced by site-
directed designed peptide mimetics on Plasmodium’s bio-
logical development make these pseudopeptides a valuable
tool for future development of immunoprophylactic strat-
egies for controlling malarial infection.
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Introduction
Malaria, one of the most important public health problems
worldwide, is a lethal infectious disease that is currently
responsible for about 300–500 million clinical cases and
more than 2 or 3 million deaths per year, mainly among
children in developing countries. Malaria is caused by the
Plasmodium protozoan which is transmitted to vertebrates
by the bite of a female Anopheles mosquito. The parasite’s
asexual blood forms (merozoites and schizonts) are the
life-cycle stages which are responsible for Plasmodium
infection morbidity and mortality in the vertebrate host
(Phillips 2001; World Malaria Report 2010 2011; Singh
et al. 2004; Tuteja 2007; Hay et al. 2004). Most deaths
caused by malaria are due to Plasmodium falciparum, the
disease’s most aggressive causative agent (World Malaria
Report 2010 2011; Singh et al. 2004; Tuteja 2007; Hay
et al. 2004; Parham and Michael 2010; Paaijmans et al.
2010; D’alessandro et al. 1995).
Developing a totally effective antimalarial vaccine has
thus become a major challenge for biomedical research to
control this deadly disease. Current vaccine development
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has focused on multi-component, multi-stage, subunit-
based synthetic vaccines because obtaining an appropriate
anti-malarial immune response depends on ensuring that
several peptides can work together to attack different par-
asite targets, in combination with improved delivery sys-
tems, as the parasite cannot be regarded as a passive target
but one which dynamically adapts to any attack made by
the immune system while it is invading and living within
the host. On the other hand, growing parasite resistance to
chloroquine and other antibiotics used for its control is
becoming a non-manageable worldwide problem. Due to
all the above, finding new strategies for controlling malaria
has become an urgent need from both immunoprophylactic
and immunotherapeutic perspectives for preventing the
action of this deadly parasite.
A number of parasite molecules have been tested as
possible vaccine candidates; among them, the merozoite
surface antigen-2 (MSA-2 or MSP-2) is an attractive target
for developing new molecular tools against malaria. This is
one of the most abundant and highly polymorphic non-
structured antigens being synthesized in both trophozoite
and schizont blood stages of Plasmodium as a precursor of
274 amino acids with an estimated relative molecular
weight of 28.4 kDa. This antigen is anchored to the para-
site surface membrane through a tail of glycosylpho-
sphatidylinositol (GPI) (Eisen et al. 1998). According to
different reports, this surface antigen has been character-
ized as having a relative molecular mass ranging from 30 to
45 kDa (Adda et al. 2009; Smythe et al. 1990) and is
constituted by two genetically conserved regions, one
located at the C-terminus and the other at the N-terminus. It
also contains a polymorphic region and two semi-con-
served regions located at the center of the antigen’s pri-
mary structure, allowing two different allelic families; thus,
the MSA-2 exact molecular mass still remains a contro-
versial matter. Given the relevance of Plasmodium survival
based on this antigen and bearing in mind that people
naturally exposed to malaria produce high levels of anti-
bodies against the N-terminus portion of MSA-2 and such
humoral response has been associated with protection
against this lethal disease, we propose a site-directed non-
naturally modified N-terminus peptide sequence of MSA-2
as an important target for functional antibody induction.
With the aim of analyzing the functional role of the
MSA-227–34 epitope (27SNTFINNA34) reported by Jones
et al. (1996), which was also identified by Ocampo et al.
(2000) on a high-activity binding peptide (HABP) coded as
4044(21KNESKYSNTFINNAYNMSIR40) that binds to red
blood cells (RBCs) in a highly specific fashion, a bioin-
formatics analysis was performed using both the entire
MSA-2 primary sequence and the one of peptide 4044
located at the MSA-2 N-terminus portion (MSA-221–40).
On the other hand, a reading register for binding an
N-terminus MSA-221–40 (peptide 4044) to pockets 1–9 of
the HLA-DRb1 molecule was determined between residues
F30 and S38 according to data reported by Patarroyo et al.
(2011). The presence of this highly conserved fragment
among different Plasmodium species has led to developing
pseudopeptide solid-phase synthesis. As denoted by the
underlined residues (shown above), 4044 has three RBC-
binding motifs. The 30FIN32-binding motif located at the
central portion of the molecule was chosen as the basis for
our experimental design.
Based on the information described above, a decision
was made to maintain the 4044 primary structure intact, but
modify specific target peptide bonds in the 30FIN32 or
30Phe-Ile-Asn32 peptide sequence to produce two reduced
amide pseudopeptide analogs, each harboring only one
substituted peptide bond. Both peptide mimetics were thus
obtained as monomer and polymer forms, in agreement
with a peptide-bond modification strategy, based on a site-
directed design. The so-obtained new molecules, derived
from parent peptide 4044, were coded as w-128 (31Ile-
Asn32) and w-130 (30Phe-Ile31), with their polymer forms
being coded as w-129 and w-131, respectively. The present
work was thus aimed at presenting evidence on the impact
of introducing a modified peptide bond and its implications
in the molecule’s secondary structure, immunogenic
capacity and ability to induce functional antibodies able to
neutralize malarial infection. These isotype-defined anti-
bodies’ immunotherapeutic in vitro and in vivo potential
was assessed in the BALB/c mouse animal model by
passively transferring specific immunoglobulins to mice
challenged with lethal doses of both Plasmodium berghei
and Plasmodium yoelii strains in parallel assays. As dem-
onstrated here, peptide-mimetic-induced immunoglobulins
were able to neutralize malarial infection and so constitute
a novel immunotherapeutic tool to be further considered in
more complex animal models and may also be potentially
useful for controlling human malaria.
However, designing both 4044-derived peptide mimet-
ics represented a chemical challenge because, as recently
reported by our group, determining pseudopeptide
sequences containing isostere peptide bonds, either on
asparagine (Asn) or glutamine (Gln) residues, can make
synthesizing difficult since such precursor amino acid
aldehydes are obtained in lower than 0.5 % yields. We
have thus recently proposed a novel strategy for obtaining
both Asn and Gln aldehyde synthons based on a controlled
side-chain protection approach, as well as a suitable solvent
partition procedure affording yields higher than 80 %
(Carren˜o et al. 2011). The analog coded w-128, harboring a
reduced amide bond located just between the Ile-Asn
amino acid pair, represented an experimental challenge
in the present work. Remarkably, by using the above-
mentioned strategy both designed w-128 (31Ile-Asn32) and
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w-130 (30Phe-Ile31) peptide mimetics were successfully
obtained in normal yields, as discussed below.
Monoclonal antibodies raised against both 4044
pseudopeptides reveal a novel epitope within the MSA-
221–40 primary structure; this is constituted by the sequence
25KYSNTFIN32 at the N-terminus of MSA-2, which
overlaps portions of the former epitope reported by Jones
and the high-activity binding peptide HABP coded 4044,
reported by Ocampo (Ocampo et al. 2000). Remarkably,
these antibodies induced by well-defined molecular struc-
tural probes cross-react with polypeptides, showing two
strong bands at relative molecular weights ranging between
50.11 and 63.09 kDa in the cytosol of P. berghei ANKA
and also two strong bands in a molecular weight range
from 44.46 to 50.11 kDa in the cytosolic extract of P.
yoelii 17XL. As demonstrated, when passively transferred,
these monoclonal antibodies controlled experimental
malaria in a rodent animal model. Thus, these novel kinds
of molecular tools constituted by site-directed designed
pseudopeptides and their induced antibodies possess a high
potential for future application in controlling human
malaria.
Materials and methods
Experimental design for obtaining site-directed peptide
bond modifications on parent peptide 4044
Introducing peptide bond surrogates (denoted w[…],
according to Spatola’s nomenclature for a class of peptide
mimetics called pseudopeptides (Spatola 1983), has been
long recognized as a powerful strategy for enhancing
peptides’ biological lifetime, improving biological activity
or selectivity, designing enzyme inhibitors or inducing
particular conformational features in potential vaccine
candidates. Solid-phase synthesis for reduced amide
pseudopeptides has become an easy procedure for obtain-
ing novel structure-defined molecules.
The experimental design was based on previously
reported binding motifs present in parent peptide 4044
amino acid sequence (21KNESKYSNTFINNAYNMSIR40),
derived from the MSA-2 antigen, which has been previ-
ously described by Ocampo et al. (2000). As denoted by
the underlined residues, this sequence has three high RBC-
binding motifs, two of them being located toward the
N-terminus and the other at the center of the sequence. The
latter was selected for the molecular design of two site-
directed peptide bond modifications, due to the potential
role as B-epitopes by inducing a humoral immune response
by specific antibody stimulation. As mentioned above,
previous work by Jones has reported the 27SNTFINNA34
amino acid sequence, located at the MSA-2 surface antigen
N-terminus, as a highly immunogenic epitope (Jones et al.
1996). For all the reasons described above, the 30FIN32
amino acid sequence was taken as the target for our
molecular peptide-mimetic design for modifying peptide
bonds between the 30Phe-Ile31 and 31Ile-Asn32 amino acid
pairs to afford the reduced amide pseudopeptide coded as
w-128 and its w-129 polymer form, as well as the w-130
analog and its w-131 polymer form, respectively as
described below.
Bioinformatic analysis
Amino acid sequences from Plasmodium MSA-2 super-
family were used as input for the bioinformatic analysis.
All sequences were obtained from the Plasmodium
Genomics Resource database PlasmoDB (http://plasmodb.
org/plasmo/); the MSA-2 P. falciparum 3D7 amino acid
sequence had the gene bank PFB0300c accession number.
Subsequently, a protein blast analysis for a multiple
sequence alignment was carried out (http://blast.ncbi.nlm.
nih.gov/Blast.cgi) against the rodent malaria species Plas-
modium berghei and Plasmodium yoelii genome-reported
proteins. Thus, 11 hypothetical P. yoelii proteins matched
the MSA-2 sequence, while 5 hypothetical proteins were
found on P. berghei. On the other hand, the MSA-221–40
amino acid sequence was also used for blast analysis as
above to assess the HABP-specific primary structure. As a
result, the entire or partial amino acid sequence of the
MSA-221-40 (peptide 4044) was found in 56 hypothetical,
putative and expressed proteins of P. yoelii and 44 poly-
peptides of P. berghei, respectively.
Solid-phase synthesis and characterization
of w–[CH2–NH] reduced amide peptide mimetics
Reduced amide pseudopeptide synthesis involves both
liquid and solid phase steps. The aldehyde form for the
carboxylic acid function is obtained during the first step;
after this, t-Boc–N-protected amino acid carboxamide is
transformed into a formyl function, carried out for the amino
acid located at the N-site of the bond needed to be modified.
The second step consists of condensation of the above
t-Boc–amino acid aldehyde to the unprotected amino acid of
the growing peptide chain, located at the C-site of the bond
to be modified. This procedure is carried out using the
strategy originally reported by Fherentz and Castro (1983).
Briefly, the standard procedure for reducing the carbonyl
function of an amino acid carboxamide intermediate
derivative of a t-Boc-protected amino acid involves a
strong reduction of this carboxamide with LiAlH4 in dry
ether. This procedure affords global yields of about 80 %
for most amino acids. In spite of being a chemically clean
procedure producing few non-desirable subproducts,
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physicochemical characterization of the obtained product is
recommended, as well as that for its starting amino acid
precursor and its corresponding carboxamide derivative by
using FT-IR, thin-layer chromatography (TLC) and unidi-
mensional 1H-NMR.
t-Boc–Phe and t-Boc–Ile aldehyde forms were con-
densed to their corresponding growing peptide resin and a
second mild reduction step with NaCNBH3 was carried out
for each adduct to simultaneously obtain all target mole-
cules, coded w-128 (F–w–[CH2NH]–I), w-129 (F–w–
[CH2NH]–I, polymer form), w-130 (I–w–[CH2NH]–N) and
w-131 (I–w–[CH2NH]–N, polymer form).
All molecules were manually synthesized by tert-butyl-
oxycarbonyl (t-Boc)-based solid-phase peptide synthesis
(SPPS), following a protocol first reported by Merrifield
(1963) and later modified for multiple peptide synthesis
(Houghten 1985). Each amino acid residue was placed on
the pseudopeptide backbone, as described elsewhere
(Cushman et al. 1991; Sasaky et al. 1987). The w–[CH2NH]
surrogate was introduced by deprotected Na-amino group
resin-bound reductive alkylation with the t-Boc-protected
amino acid aldehyde (0.576 mmol) in DMF containing
0.5 % acetic acid (HOAc), followed by portion-wise addi-
tion of NaBH3CN (0.670 mmol) for 40–60 min. Total
coupling was checked by the ninhydrin test and the cou-
pling reaction was repeated when necessary. Coupling was
allowed to proceed for 5 h with constant shaking, followed
by several washes with N,N0-dimethylformamide (DMF),
isopropanol and dichloromethane. Standard solid-phase
peptide synthesis was carried out to introduce the remaining
t-Boc amino acids to the last N-terminal residue. Protected
pseudopeptide-resin batches were treated with trifluoro-
acetic acid (TFA) and cleaved from the resin by treatment
with low concentrations of anhydrous hydrogen fluoride
(HF), containing 10 % anisole at 0 C for 60 min. After HF
evaporation in an N2 stream, each pseudopeptide-resin
product was washed with cold diethyl ether, then extracted
with 5 % HOAc and finally lyophilized. The raw products
obtained for each w–[CH2NH] surrogate were further ana-
lyzed by analytical RP-HPLC, purified by preparative
RP-HPLC and identified by MALDI-TOF mass spectrometry.
Polymer forms for both reduced amide pseudopeptides
(coded w-129 and w-131) had identical amino acid
sequences regarding their corresponding monomers w-128
and w-130, but were different regarding their N- and
C-terminals, the polymer forms containing a Cys-Gly pair of
residues at the N-end and a Gly-Cys pair of residues at the
C-terminus. After being cleaved from the resin, these
polymer forms were dissolved in isotonic saline solution at
4 mg/mL concentration and bubbled in an N2 stream at
room temperature, pH 7.4, until no thiol free groups were
detected. This procedure was carried out using the Elman
reaction, proving that all sulfhydryl groups were involved in
the intermolecular disulfide bridges. Table 1 shows the main
physical and chemical characteristics for all molecules.
Peptide mimetics were obtained in average yields of
about 70 % and their guaranteed purity was higher than
99 %, as judged by RP-HPLC. Their identity was assessed
by MALDI-TOF mass spectroscopy. Monomer forms for
each target molecule were also characterized by uni- and
bi-dimensional 1H-NMR techniques, as will be discussed
below.
Thin-layer chromatography (TLC)
Thin-layer chromatography was used to assess t-Boc-
amino acid aldehyde formation on silica gel pre-coated
aluminum plates (F254 silica gel 60, Merck, Darmstadt,
Germany), using some of the following solvent systems:
EtAcO-n-hexane (2:1), EtAcO-n-hexane (1:1) or a solvent
system based on CHCl3–MeOH (2:1), as suitable. Amino
acid derivatives were analyzed by fluorescence at short UV
wavelength (254 nm), or ninhydrin by a follow-up
reaction.
Fourier transformed-infrared spectroscopy (FT-IR)
Infrared spectra for all N-a-t-boc–Asn and N-a-t-boc–Gln
side-chain protected amino acids and their derivatives were
recorded on a Jasco FT/IR-460 plus spectrophotometer
(Tokyo, Japan). Samples were analyzed on a PIKE MIR-
acle AG single reflection horizontal ATR cell (Pike
Technologies, Madison, WI, USA) by dispersing either a
lyophilized compound or its suspension, subjected to 21 psi
(pounds/square inch) pressure. Spectra were recorded after
64 scans at 4 cm-1 resolution.
Table 1 Physical and chemical
characteristics of the peptide
MSA-221-40 and its
pseudopeptide analogs
Code Amino acid sequence Theoretical
MW (Da)
Experimental
m/z [M ? H?]
4044 KNESKYSNTFINNAYNMSIR 2,388.01 2,386.05
4306 CGKNESKYSNTFINNAYNMSIRGC 2,715.50 2,713.13
w-128 KNESKYSNTF–w[CH2–NH]–INNAYNMSIR 2,379.14 2,380.03
w-129 CGKNESKYSNTF–w[CH2–NH]–INNAYNMSIRGC 2,706.64 2,710.31
w-130 KNESKYSNTFI–w[CH2–NH]–NNAYNMSIR 2,379.14 2,380.09
w-131 CGKNESKYSNTFI–w[CH2–NH]–NNAYNMSIRGC 2,706.64 2,704.26
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Mass spectrometry analysis by MALDI-TOF
Mass spectra were recorded on a Bruker Protein TOF mass
spectrometer with reflectron mode (Billerica, MA, USA).
MALDI (matrix-assisted laser desorption ionization)
experiments were performed using the TOF (time of flight)
technique. This instrument uses an N2 laser, radiating at
337-nm wavelength with 3-ns pulses. The acceleration
voltage was ?17.5 kV and reflectron voltage was ?20 kV.
All spectra were obtained by a respective series of ten laser
pulses to ensure comparable conditions. Laser power was
as minimal as possible for each measurement. The matrix
used in this work was a-cyano-4-hydroxycinnamic acid
(CCA) (Sigma Chemical Co., Saint Louis, MO). The CCA
matrix was prepared as a saturated solution in 1 mL TA
(40 % acetonitrile in 0.1 % trifluoroacetic acid). Samples
were dissolved in TA to give a 100 pmol/lL concentration.
Samples were prepared for MALDI-TOF analysis by
diluting the sample solution in the matrix-saturated solu-
tion to reach a 10 pmol/lL concentration. Then, 0.5 lL
aliquots of sample-matrix mixture was poured onto the
target plate, air-dried and analyzed.
Circular dichroism (CD) experiments
Circular dichroism (CD) assays were carried out at room
temperature on nitrogen-flushed cells using a Jasco J-810
spectropolarimeter (Madrid, Spain). Spectra were recorded
within a 190–260-nm wavelength interval, using a 1-mm
path-length rectangular quartz cell. Each spectrum was
obtained from averaging three scans taken at a 20 nm/min
scan rate with 1-nm spectral bandwidth corrected for
baseline deviation using Jasco software. The CD profile for
each molecule was obtained by dissolving lyophilized
purified peptides in water or 30 % aqueous 2,2,2-trifluo-
roethanol (TFE), 0.5 mL final volume. A typical 0.2 mM
peptide/pseudopeptide concentration in TFE–water mixture
was stabilized but did not induce secondary structure in
peptides, as described elsewhere (Lozano et al. 2007). The
results were expressed as mean residue ellipticity (h), the
units being deg 9 cm2 9 dmol-1 according to the
(h) = hk/(100lcn) function, where hk is measured elliptic-
ity, l the optical path length, c peptide/pseudopeptide
concentration and n the number of amino acid residues in
the sequence of interest.
Secondary structure analysis by proton nuclear
magnetic resonance (1H-NMR)
For NMR measurements, 10 mg of each lyophilized pep-
tide or pseudopeptide analog was dissolved in a H2O/D2O
mixture (9:1 ratio), as well as in an aqueous 30 % TFE
solution (99.94 % D 2,2,2-trifluoroethanol-d3, Cambridge
Isotope Laboratories, Andover, MA, USA) until reaching a
final 0.5 mL volume. Proton nuclear magnetic resonance
(1H-NMR) spectra were recorded on a Brucker DRX
600 MHz spectrophotometer, provided with a temperature
control unit. Spectra were recorded between 280 and 310 K
using 4.5–5.0 pH range and referenced to water’s internal
signal at 4.75 ppm. Routine COSYGSmtprtp (Avance
version, Phase Sensitive) was performed to assign all spin
systems, using gradient pulses for detection with multiple-
quantum filter, according to gradient-radio experiments.
TOCSY mievgstp 19 (Avance version, Homonuclear
Hartman-Hahn Transfer), using mLEV 17 sequence mixing
and 80–100 ms mixing-time, was carried out to corroborate
NH and CaH side-chain connectivities for each spin sys-
tem. Experiments (Advance version, 2D-Homonuclear
Correlation via Dipolar Coupling Phase Sensitive using
TPPI) were carried out for 150, 200–300, 400 and 500-ms
mixing times to assign all sequential neighbors for the
NOESY gstpi9-peptide chain. The 2D data were processed
on a Silicon Graphics-Brucker Indy computer provided
with XWINNMR 1.3 software (Bruker, Darmstadt,
Germany).
Temperature coefficients were determined from TOCSY
spectra using a 285–315 K temperature range. A slope was
deduced from a linear relationship established for chemical
shift cf temperature pattern for each hydrogen from the
amide groups (-DdHN/DT, ppm/K). 3JHNHa coupling
constants were measured from the separation of multiplets
in cross-peaks from unidimensional DFQ-COSY
experiments.
Structural calculation
The structural calculation was performed by using the
software provided by Accelrys in Silicon graphics work-
stations. NOE peaks, selected from 400 ms NOESY data
sets, were integrated and converted into distance restraints.
These restraints were grouped as strong, medium and weak
corresponding to 1.8–2.5 A˚, 2.5–3.5 A˚ and 3.5–5.0 A˚
distance restraints, respectively. Distance Geometry (DGII)
software was used for producing 50 starting structures for
each analyzed molecule, in this case peptide 4044 and its
peptide mimetics w-128 and w-130. These resulting 50
conformers were molecularly refined using a strategy
known as restricted molecular dynamic (rMD) as previ-
ously described (Havel et al. 1985).
Producing poly- and monoclonal antibodies for w-128
(w-129) and w-130 (w-131) peptide mimetics
and immunochemical tests
Polyclonal antibodies induced by 4044-reduced amide
pseudopeptides were produced in Aotus monkeys after
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being administered in three groups of eight animals each
with polymer forms of the native 4044 peptide and its
reduced pseudopeptide analogs in a three-dose scheme, by
formulating 250 lg of each immunogen dissolved in iso-
tonic saline solution and emulsified with Freund’s Com-
plete Adjuvant for the first administration and Freund’s
Incomplete Adjuvant for the two boosts. Samples of blood
from treated animals were obtained after the second and
third administrations and sera samples were kept frozen
until use for immunochemical experiments. Animals were
maintained according to international and Colombian reg-
ulations for animal welfare in the FIDIC animal colony
station located in the city of Leticia, Amazonas.
In parallel experiments, spleen cells from BALB/c mice,
previously immunized with pseudopeptide polymers w-129
and w-131, were fused to murine X63Ag8 myeloma cells
using polyethylene glycol 3,000–3,700 (Sigma Chemical
Co., St. Louis, MO, USA), according to previously
described methodology, to obtain reactive hybridomas, as
originally proposed by (Kohler and Milstein 1976; Lozano
et al. 2007). These hybridomas were cloned twice by
limiting dilution in flat-bottomed 96-well plates; superna-
tants were assessed for specific antibody reactivity by
ELISA and Western blot. Cell clones having specific
reactivity were amplified to higher cell culture volume.
ELISA
Enzyme-linked immunosorbent assays (ELISA) were car-
ried out for detecting antibody presence and measuring Ig
isotypes pools after being purified. Briefly, each ELISA
microplate well (Nunc, Inter, Med, Denmark) was coated
with 100 lL of 0.005 lg/lL pseudopeptide as well as with
P. falciparum lysate dissolved in bicarbonate buffer, pH
9.63. 100 lL samples of pure Ig pools (diluted 1:100 at an
average concentration of 0.4 lg/mL) were tested in
duplicate after blocking wells with 3 % skimmed milk in
0.05 % PBS-Tween-20. Specific anti-tested compound
activity was detected using a 1/1,000 goat anti-rabbit IgG
(H ? L) peroxidase conjugate (Vector Laboratories, Inc.
Burlingame, CA, USA). A tetramethylbenzidine (TMB)
developing solution (KLP, Gaithersburg, MD, USA) was
used as the substrate. The reaction was stopped by adding
50 lL of 1 M H3PO4 per well. Results were expressed as
OD values, obtained at 450 nm.
Immunoblotting
The P. falciparum, P. berghei and P. yoelii-schizont
lysates were dissolved in Laemmli’s buffer, using
b-mercaptoethanol as reducing agent and resolved either on
fixed 10 % or on 7.5–15 % gradient gels by SDS-poly-
acrylamide gel electrophoresis (Green 1978). The resolved
proteins were electro-transferred to a nitrocellulose mem-
brane (Smythe et al. 1988). The antibody Ig pools or
monoclonal antibodies were used as primary antibodies
and detected using goat anti-mouse IgG (H ? L) alkaline
phosphatase conjugate (Vector Laboratories, Burlingame,
CA, USA). A BCIP/NBT solution (Promega, Madison, WI,
USA) was used as reaction substrate.
In vitro IgM switching to IgG isotype
A thymocyte-conditioned medium was prepared according
to a previously reported strategy (Pardue et al. 1983) to
stimulate lymphocyte and cytokine proliferation in the
presence of either w-128 or w-130 antigen, respectively.
BALB/c mice thymuses were surgically removed from
2- to 4-week-old animals; the thymus cells were then cultured
for 48 h at 37.8 C in 5 % CO2 in RPMI 1640 medium,
containing 10 % FBS. The thymocyte-conditioned medium
(TCM) was then harvested by centrifuging (1,500 rpm for
5 min to pellet the thymus cells) and the supernatant
(TCM) was stored at -20 C until use. Cell clones were
originally coded as 1A8A8, induced by the w-130
(30F–I31), and the 1H10E5G6 clone was induced by w-128
(31I–N32) antibodies, secreted by both cell clones strongly
cross-reacting with both native and denatured MSA-2
antigen from the human malaria P. falciparum FCB2
strain. Cells were dispersed at 100,000 cells per well in flat-
bottomed 96-well plates. Cells were then pulsed seven
times with 200 ng of either w-130 or w-128, previously
diluted in RPMI 15 % FBS and 50 % TCM, at intervals of
8–15 days per pulse. Cell supernatants were periodically
harvested to determine their antibody isotype by using a
Monoclonal Antibody Isotyping Kit (HRP/ABTS) from
Thermo Scientific (Rockford, IL, USA). w-128 (w-129)-
induced clones were coded 6 and 7 and those induced by w-
130(w-131) were coded G, M, O and Q.
In vivo production of w-129 and w-131
peptidomimetic-induced monoclonal antibodies
Macrophages were stimulated in the peritoneal cavity of
BALB/c mice by ip administration of 0.5 mL pristane
(Sigma Chemical Co., Saint Louis, MO, USA) for scaling
up the production of each monoclonal antibody. Eight days
after each animal had received the ip injection, 1 9 106
cells of cell clone were induced by both w-129 and w-131,
suspended in a 0.5 mL RPMI-1640 base. Ten days after
cell inoculation, the ascitic fluid so produced was collected
by an abdominal puncture made with a sterile needle; this
was then stored at -20 C until use. When a sufficient
amount of each fluid had been collected, the complement
was deactivated for 30 min at 56 C and then centrifuged
at 800 rpm for 5 min at 4 C; the lipid material was
918 J. M. Lozano et al.
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removed and subsequently immunoglobulin purified
(Lozano et al. 2007).
Immunoglobulin isolation and purification
Antibodies specific for each pseudopeptide were then
selectively precipitated by saturation with 80 % ammo-
nium sulfate to obtain anti-pseudopeptide specific anti-
bodies from ascitic fluids and clone cell culture
supernatants. After spinning, supernatants were carefully
removed and precipitated antibodies were reconstituted
using 10 mM Tris–HCl pH 8.5 and dialyzed against the
same buffer on a Spectra-pore dialysis membrane (Hous-
ton, Texas, USA) at 4 C.
Weak anionic exchange chromatography (AEC) was
performed with the antibody-enriched dialyzed precipitates
obtained from reactive rabbit sera using DEAE-Sephadex
A-25 resin (Pharmacia, Uppsala, Sweden) previously
equilibrated with 10 mM Tris–HCl buffer, pH 8.5. Anti-
bodies were left to bind at 4 C overnight with constant
shaking. After the column had been appropriately packed,
Igs were eluted from the column by progressively
increasing the buffer’s ionic strength from 50, 100 to
500 mM NaCl. A total of four column volumes (250 mL)
were added per step, collecting 10 mL fractions at a con-
stant 0.5 mL/min flow rate. The resin was then re-equili-
brated with 10 mM Tris–HCl buffer, pH 8.5. All elution
fractions were characterized by direct Dot blot for Ig
detection and positive fractions were submitted to indirect
Dot blot against a P. falciparum lysate, as well as against
each 4044 pseudopeptide. Reactive elution fractions from
direct and indirect Dot blots were pooled, taking into
account the ionic strength order in which they had been
eluted. Pooled fractions were subsequently dialyzed against
PBS at 4 C. Each Ig pooled fraction’s purity was assessed
by sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE). Further characterization was performed
to define Ig reactivity against a P. falciparum lysate by
Western blot.
Ig protein determination
Each Ig pool’s protein concentration was determined by
using a micro BCA protein assay (Pierce, Rockford, Illi-
nois, USA). Pure pooled Ig samples from the original
stocks were diluted 1/10 to 1/100 times in isotonic saline
solution and 200 lL of the reagent A (bicinchoninic acid)
and B (Cu2?) mixture was then added, according to the
manufacturer’s recommendations. Samples were incubated
in duplicate at 37 C for 30 min before optical density was
measured (OD) at 570 nm. Each sample protein concen-
tration was determined by comparing its absorbance
against a calibration curve, obtained from 0 to 8 lg
samples from a 2 mg/mL BSA standard diluted in PBS.
The color complex was stabilized by adding 50 lL of 1 N
NaOH.
P. falciparum recombinant MSP-2 expression
and purification
Portions of the human PfMSP-2 P. falciparum 3D7 protein
coding gene (Pf3D7_02) was cloned in the pQE-30 expres-
sion vector, which adds a 6-histidine tail to its N-terminal
region. The recombinant plasmid was transfected in E. coli
RG and the strain was cultivated in Terrific Broth medium
(TB) (12 g/L tryptone, 24 g/L yeast extract, 4 mL/L glycerol,
2.31 g/L KH2PO4 and12.54 g/L K2HPO4), supplemented
with ampicillin (0.1 mg/L) and chloramphenicol (0.034 mg/L)
for 12 h at 37 C with constant shaking. 950 mL TB med-
ium was then inoculated with continuous shaking at 37 8 C
until reaching 0.6–0.8 OD at 600 nm. Recombinant protein
expression was induced by adding IPTG (isopropyl-
b-D-thiogalactopyranoside) at 1 mM final concentration and
incubating for 5 h at 37 C. After centrifuging at
10,000 rpm for 30 min, the pellet was treated with dena-
turing agents (6 M urea, 10 mM Tris–HCl, 100 mM
NaH2PO4 and 15 mM imidazole) and lysozyme (1 mg/mL).
The sample was sonicated and centrifuged at 12,000 rpm for
35 min at 48 C for collecting the supernatant and subse-
quently submitting it to SDS-PAGE and Western blotting to
ascertain recombinant protein expression.
In vitro malarial invasion inhibition
by pseudopeptide-induced antibodies
Antibodies were tested for their ability to inhibit P. falci-
parum (FCB-2 strain) invasion of human RBCs in in vitro
assays. Ring-stage-iRBCs ([5 % parasitemia) were syn-
chronized using the sorbitol technique (Lambros and
Vanderberg 1979) and incubated in complete RPMI 1640
media supplemented with 25 mM HEPES buffer, 1 mg/mL
hypoxanthine, 40 lg/mL gentamicin, 5 U/mL penicillin,
2 g/L glucose, 5 % NaHCO3 and 10 % 0 ? plasma. When
parasites had reached the schizont stage, 96-well plates
containing three antibody dilutions (1:2, 1:4 and 1:8) were
seeded with cultured iRBCs and additional non-iRBCs for
completing a final 100 lL volume per well at 1.5 %
hematocrit and 0.3 % parasitemia. All antibodies were
assessed in triplicate, being incubated for 18 h at 37 C in
5 % O2, 5 % CO2, and 90 % N2. Cells were harvested after
centrifugation and 50 lL supernatant was removed and
replaced by 100 lL, 15 lg/mL hydroethidine. The pellet
was resuspended in 300 lL PBS following further incu-
bation at 37 C for 30 min and washed with PBS, then
poured into polystyrene tubes and quantified for parasite-
mia by flow cytometry using a FCAScan equipment
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(Becton–Dickinson, San Jose´, CA, USA). The sequence of
events was recorded and analyzed using Cell Quest soft-
ware. An FSC x FL2 profile was used for establishing an
inclusion gate for non-iRBCs. Parasitized RBCs were then
quantified by quadrant analysis. Normal RBCs and para-
sitized RBCs in 15 lg/mL ethylene glycol tetraacetic acid
(EGTA) were used as controls. Invasion inhibition was
calculated as 100 9 (% parasitemia in control - %para-
sitemia in test)/(% parasitemia in control).
Standardizing Plasmodium berghei and Plasmodium
yoelii infection in BALB/c mice
Cryopreserved P. yoelii 17XL and P. berghei ANKA rodent
malarial strains stored in Krebs solution (0.85 % NaCl, 5 %
glucose and 4.2 % (p/v) sorbitol) were thawed, heated at
37 C and subsequently washed with a non-supplemented
RPMI medium to produce in vivo malarial infection in
BALB/c mice (obtained from the Universidad Nacional de
Colombia’s mouse-breeding facility). The obtained strain,
having 80 % viability, was centrifuged at 1,500 rpm for
5 min, as previously reported (Ramos-Avila et al. 2007;
Spencer-Valero et al. 1998; Lewis-Hughes and Howell
1984; Mons et al. 1983); the pellet containing about 1 9 107
infected red blood cells (iRBCs) was suspended in 1 mL
RPMI and immediately used for intraperitoneally inocu-
lating five BALB/c mice, each administered with an aver-
age of 2 9 106 iRBCs. Parasitemia in all infected animals
was monitored by Wright staining of blood smear, showing
that mice became parasitized by the second to sixth day
after infection, and that parasitemia levels increased slowly
until animals died 10–12 days after having been infected
(Ramaiya et al. 1987; Smalley and Butcher 1975).
Given the importance of establishing appropriate in vitro
models for testing potential anti-malarial agents against
different Plasmodium strains, such as those causing rodent
malaria, a key step is to maintain a cell culture consisting
of some of these agents for periods longer than 10 days.
One of the goals of this work was to establish two rodent
malarial strains in a controlled cell culture (Plasmodium
berghei and Plasmodium yoelii).
Antimalarial in vivo activity of antibodies induced
by MSA-2 peptide mimetics
Groups of five BALB/c mice were used for testing each
antibody sample. Groups were distributed as follows: iso-
tonic saline solution was used for group 1 (control group),
clone 6 eluted at 100 mM Ig anti w-129 for group 2, clone
7 eluted at 50 mM Ig anti w-129 for group 3, clone 7 eluted
at 100 mM Ig anti w-129 for clone 4, 50 mM Ig anti w-131
for clone 5, 100 mM Ig anti w-131 for clone 6 and 500 mM
Ig anti w-131 for clones 7 and 8. A non-relevant polyclonal
serum from a mouse immunized with Papilloma virus-like
particles (VLPs) was used as negative control.
Antibody passive transfer experiments had the following
scheme: the first passive transfer was conducted on day -1
by iv administration of 250 lL Igs for each individual. Mice
were infected with 50,000 P. berghei iRBCs/lL adminis-
tered in isotonic saline solution on day 0. The second and
third passive transfers were made on days 2 and 4 by
administering the same immunoglobulin dose. Parasitemia
percentage was evaluated from day 6 to 20. A second
malaria infection was made on day 21 by ip administration
of 100,000 P. berghei iRBCs/lL. The 4, 5 and 6th passive
transfers were made on days 25, 28 and 30 using similar Ig
dose to the starting ones, by iv administration. Percentage
parasitemia was assessed from day 25 to day 40.
Immunoglobulin passive transfer experiments and
BALB/c mouse challenge with P. yoelii were made by
forming groups of four to five animals as follows: groups 1
and 10 were injected with isotonic saline solution, group 2
with chloroquine, group 3 with Ig anti w-129-6-50 mM,
group 4 with Ig anti w-129-6-100 mM, group 5 with Ig anti
w-129-7-50 mM, group 6 with Ig anti w-129-7-100 mM,
group 7 with 50 mM Ig anti w-131, group 8 with 100 mM
Ig anti w-131 and group 9 with 500 mM Ig anti w-131.
Given the stronger virulence of P. yoelii compared to the
P. berghei strain, the immunization scheme was modified
as follows: the first passive transfer was carried out on day
-1 by administering iv 250 lL Igs to each individual.
Mice were iv infected with P. yoelii on day 0 by injecting
2,000 iRBCs/lL. The second and third passive transfers
were performed on days 2 and 5 using a dose equivalent to
the first. Parasitemia percentage was assessed from day 6 to
28. A second malaria infection with P. yoelii was carried
out on day 13 by ip injection of 5,000 iRBCs/lL. The 4th
passive transfer was conducted on day 15, using a similar
dose of Ig. The experimental challenge with P. yoelii for
groups 7, 8, 9 and 10 was conducted following the fol-
lowing scheme. The first passive transfer was carried out
on day 0, by iv injecting 100 lL Igs per animal. Experi-
mental infection was made on the same day by iv injecting
2,000 P. yoelii iRBCs/lL. Animals were passively trans-
ferred on days 1, 2 and 4 with 200 lL Igs per mouse.
Parasitemia appearance was assessed from days 3 to 9.
Results
Bioinformatics
Blast tool for multiple alignment of protein fragments
performed based on the MSA-221–40 or 4044 peptide
sequence demonstrated significant high homology and
identity percentages with hypothetical, putative and
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orthologous sequences on Plasmodium rodent malaria
species such as P. berghei and P. yoelii.
Since so far MSA-2 has no reported orthologous
sequences in the P. yoelii genome, using the peptide 4044
amino acid sequence as the basis to be analyzed against all
proteins reported for P. yoelii and P. berghei, an important
number of hypothetical, putative and expressed protein-
genes were found, 56 and 44, respectively, all of them
located in different cell compartments such as nuclei, cytosol
and in specific organelles such as rhoptries. Some represen-
tative examples from the whole obtained data show that on
comparing the Plasmodium falciparum MSA-221–40 amino
acid sequence, a fragment from 22N to I39 has a 67 % identity
and 78 % homology with a Plasmodium berghei strain
ANKA transcription initiation TFIID-like coded PB000459.
Similarly from the same P. falciparum MSA-2, the fragment
22N to I39 has a 61 % identity and 72 % homology with a
TATA element modulatory factor of Plasmodium yoelii
strain 17XL. Also, a 17-residue fragment from 22N to M37 on
the P. falciparum MSA-221–40 peptide has an 80 % identity
and 80 % homology with a Plasmodium yoelii hypothetical
protein PY06720 and 64 % identity and 71 % homology for
a P. falciparum MSA-221–40 with a 16-residue fragment from
23E to Y35 located in the hypothetical protein PY05325 of
Plasmodium yoelii strain 17XL. On the other hand, the
15-residue fragment from the P. falciparum MSA-221–40
peptide has a 64 % identity and 71 % homology with a
fragment located on the putative protein coded PB500001 of
Plasmodium berghei strain ANKA.
Remarkably, a 15-residue peptide from 22N to Y35 from
the P. falciparum MSA-221–40 was identified in the eryth-
rocyte membrane protein 3 PFEMP3, PY02048 (gene bank
EAA21466.1) of Plasmodium yoelii yoelii 17XNL having
64 % of identity and 64 % homology and an 18-residue
fragment from 21K to S38 of the P. falciparum MSA-221–40
peptide was identified in the putative yir2 antigenic protein
of Plasmodium yoelii yoelii having 56 % identity and 56 %
homology as well as in the putative yir1 protein of P. yoelii
yoelii peptide fragment from 21K to Y35 having 60 %
identity and 67 % homology; other gene identified as shar-
ing a 15-peptide sequence was the putative yir4 protein gene
bank codes EAA22494.1 and EAA22744.1 having 60 and
53 % of identity, respectively. Also a 19-residue fragment
of the P. falciparum MSA-221–40 peptide was identified in
the maebl hypothetical protein of Plasmodium yoelii yoelii
17XNL as PY03552, gene bank code EAA15281.1. Among
several examples, a 16-peptide fragment of the N-terminal
MSA-2 P. falciparum antigen, a 16-residue peptide from
26Y to N36 was identified in the vesicle transport protein of
Plasmodium berghei strain ANKA genome coded
PB000004, EMB code CAH93534.1, having 73 % identity
and 82 % homology as well as a 17-residue peptide from
28N to M37 was found in the glycoxalate II family protein,
putative of Plasmodium berghei strain ANKA coded as
PB000214.01 and EBM: CAH95663.1, having 67 % iden-
tity and 67 % homology. A 19-residue fragment in the same
region has a 46 % identity with the 235 kDa rhoptry protein
EAA16521.1, PY04630 of P. yoelii yoelii and 53 % identity
with the reticulocyte binding protein CAI02683.1 and 73 %
identity with the putative N-acetyltransferase EMB code
CAI04236.1, PB000192.01 of Plasmodium berghei in a
19-residue peptide from 30F to I39. Other peptide homologs
were found in the protein phosphatase EAA21747.1 of P.
yoelii with 78 % identity as well as 43 % with the
mechanoselective ion channel putaitive protein EAA17950.1,
PY05855 of P. yoelii.
Designing, synthesis and structural characterization
of high binding MSA-2-derived peptide 4044 and its
amide-reduced peptide mimetics
As mentioned, peptide coded 4044 (MSA-221-40) is loca-
ted in conserved block 1 of the conserved amino-terminal
region in the MSA-2 antigen sequence as observed in
Fig. 1. This protein portion is unstructured as determined
by 1H-NMR experiments conducted in solution. The RBC
binding motif, defined by the 30F–I–N32 residues, served as
the basis for designing a single peptide bond site-directed
substitution by the w–[CH2–NH] isostere bond, producing
w-128 (F–I) and w-130 (I–N) pseudopeptides and their
corresponding polymeric forms, w-129 and w-131,
respectively as shown in Fig. 2. The synthetic transfor-
mation of N-a-amino protected phenylalanine t-Boc-L–
Phe–OH to a required t-Boc-L–Phe–H amino aldehyde
form as the building block to be further incorporated into a
growing peptide resin-defined sequence is displayed in
Fig. 3. This two-stage strategy includes derivatizing com-
pound (1) to its carboxamide form to protect the amino acid
carbonyl carbon which is treated later with a strong
reducing agent, aluminum and lithium hydride, to form a
five-member partial ring including lithium, which is then
hydrolyzed to generate the amino acid aldehyde form (2).
Compound (3) harboring the iminium ion is susceptible to a
specific reduction with sodium cyanoborohydride (NaC-
NBH3), to allow (4). The process has an overall 60–70 %
yield represented by compound (5) when carried out with
any given amino acid, except asparagine and glutamine
(Asn and Gln) which need to be treated in a different way,
as discussed elsewhere (Carren˜o et al. 2011).
Spectroscopic characterization of t-Boc–Phe and
t-Boc–Ile amino acids and their derivatives
t-Boc-L–Phe derivatives
t-Boc-L–Phe–OH, Rf = 0.40 ethyl acetate:n-hexane (1:2).
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1H-NMR (dimethylsulfoxide-D6 (D, 99.9 %)): d =
1.42 ppm (9H, C(CH3); d = 2.66 ppm (2H, Hb); d =
5,76 ppm (1H, Ha); d = 7,17 ppm (2H, H2-6-aromatic
ring); d = 7,22 ppm (2H, H3-5-ring) d = 7,23 ppm (2H,
H4-aromatic ring); d = 7,28 ppm (1H, NHa); d =
2.5 ppm (m, 6H, dimethyl sulfoxide).
Fig. 1 Schematic structure of
the merozoite surface antigen-2.
MSP-2 gene block organization
is represented by different
colors in regions and denoted by
numbers from 1 to 5,
highlighting the 4044 peptide
NMR-solution structure located
at the molecule N-terminal.
Critical binding residues are
underlined. MSA-2 is anchored
to the parasite surface by a GPI
motif
Fig. 2 Experimental design for the site-directed synthesis of
pseudopeptides w-128 and w-130. The amide type peptide bond
[CO–NH] was substituted for its reduced amide isostere bond w–
[CH2NH] between residues
30Phe-Ile31 in analog w-130, and between
residues 31Ile-Asn32 to produce analog w-128
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FT-IR (amorphous solid): m(cm-1) = 3,299.14, 3,246.12,
2,974.23, 1,707.43, 1,644.67, 1,496.54, 1,405.60, 1,359.34,
1,272.23, 1,156.45, 774.09.
t-Boc-L–Phe–N(CH3)OCH3, Rf = 0.50 ethyl acetate:n-
hexane (1:2).
1H-NMR (dimethyl sulfoxide-D6 (D, 99.9 %)):
d = 1.39 ppm (9H, C(CH3); d = 2.81 ppm (2H, Hb);
d = 3,18 ppm (3H, N–(CH3)); d = 3,65 ppm (3H, N–O–
(CH3)); d = 5,25 ppm (1H, Ha); d = 7,19 ppm (2H, H2-
6-aromatic ring); d = 7,24 ppm (2H, H3-5-aromatic ring)
d = 7,25 ppm (2H, H4-aromatic ring); d = 7,28 ppm
(1H, NHa); d = 2.5 ppm (m, 6H, dimethyl sulfoxide).
FT-IR (oiled film): m(cm-1) = 3,299.14, 3,246.12,
2,974.23, 1,894.98, 1,657.14, 1,644.67, 1,496.54, 1,405.60,
1,359.34, 1,272.23, 1,156.45, 774.09.
t-Boc-L–Phe–H, Rf = 0.69 ethyl acetate:n-hexane
(1:2).
1H-NMR (dimethyl sulfoxide-D6 (D, 99.9 %)):
d = 1.48 ppm (9H, C(CH3); d = 2.81 ppm (2H, Hb);
d = 5,01 ppm (1H, Ha); d = 7,17 ppm (2H, H2-6-aro-
matic ring); d = 7,23 ppm (2H, H3-5-aromatic ring)
d = 7,25 ppm (2H, H4-aromatic ring); d = 7,32 ppm
(1H, NHa); d = 9,63 ppm (1H, formyl); d = 2.5 ppm (m,
6H, dimethyl sulfoxide).
FT-IR (oiled film): m(cm-1) = 3,360.43, 3,246.12,
2,974.23, 1,677.05, 1,644.67, 1,496.54, 1,405.60, 1,359.34,
1,272.23, 1,156.45, 774.09.
t-Boc-L–Ile derivatives
t-Boc-L–Ile–OH, Rf = 0.66 ethyl acetate:n-hexane (1:1).
1H-NMR (dimethyl sulfoxide-D6 (D, 99.9 %)):
d = 0,94 ppm (3H, Hc); d = 0,97 ppm (3H, Hd);
d = 1,20 ppm (2H, Hc); d = 1.45 ppm (9H, C(CH3));
Fig. 3 Solid-phase synthesis of malaria MSA-2 antigen-derived
peptide mimetics. (1) The amino primary function of Asn residue in
the sequence anchored to the methylbenzhydrylamine resin (MBHA)
was condensed with the carbonyl carbon of synthon t-Boc-L–Ile–H
(2), thereby forming the iminium ion in the product (3). The
formation of this ion led to a methylene group formation in product
(4) after being treated with the NaCNBH3 reducing agent. After
incorporating the remaining normal amino acids into the peptide
chain, the final expected product, w-130 (5), was generated when it
was cleaved from the resin by treatment with low and high HF
concentrations. SPPS was used for solid-phase peptide synthesis
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d = 1,92 ppm (1H, Hb); d = 4,29 ppm (1H, Ha);
d = 7,25 ppm (1H, NHa); d = 2.5 ppm (m, 6H, dimethyl
sulfoxide).
FT-IR (amorphous solid): m(cm-1): 3,352.65, 3,299.24,
2,963.19, 1,726.67, 1,699.54, 1,673.08, 1,530.43, 1,451.60,
1,412.79, 1,299.21, 1,160.34, 1,016.01, 776.44.
t-Boc-L–Ile–N(CH3)OCH3, Rf = 0.54 ethyl acetate:n-
hexane (1:1).
1H-NMR (dimethyl sulfoxide-D6 (D, 99.9 %)): d =
0,89 ppm (3H, Hc); d = 0,93 ppm (3H, Hd); d = 1,12 ppm
(2H, Hc); d = 1.43 ppm (9H, C(CH3)); d = 2,80 ppm (1H,
Hb); d = 3,21 ppm (3H, N–(CH3)); d = 3,78 ppm (3H, N–
O–(CH3)) d = 4,61 ppm (1H, Ha); d = 7,25 ppm (1H,
NHa); d = 2.5 ppm (m, 6H, dimethyl sulfoxide).
FT-IR (powdered): m(cm-1): 3,352.65, 3,299.24,
2,963.19, 1,699.54, 1,688.14, 1,654.77, 1,530.43, 1,451.60,
1,412.79, 1,299.21, 1,160.34, 1,016.01, 776.44.
t-Boc-L–Ile–H, Rf = 0.58 ethyl acetate:n-hexane (1:1).
1H-NMR (dimethyl sulfoxide-D6 (D, 99.9 %)): d =
0,91 ppm (3H, Hc); d = 0,94 ppm (3H, Hd); d = 0,96 ppm
(2H, Hc); d = 1.45 ppm (9H, C(CH3)); d = 2,03 ppm (1H,
Hb); d = 4,37 ppm (1H, Ha); d = 7,25 ppm (1H, NHa);
d = 9,66 ppm (1H, formyl); d = 2.5 ppm (m, 6H, dimethyl
sulfoxide).
FT-IR (oiled film): m(cm-1): 2,963.21, 1,693.09,
1,530.43, 1,451.60, 1,412.79, 1,299.21, 1,160.34, 1,016.01,
776.44.
Subsequently, the synthon (3) was incorporated into the
in situ growing peptide chain during synthetic solid phase
to be submitted to a second reduction in gentler conditions
using sodium cyanoborohydride (NaCNBH3), thereby
producing target peptide mimetics (as shown in Fig. 3). As
mentioned above, the physicochemical characteristics of
the molecules produced for this study can be observed in
Table 1, defined as native peptide 4044 and its pseudo-
peptide analogs in their monomeric and polymeric forms.
All these molecules had the proper molecular qualities
required for carrying out immunological assays and in all
cases overall yields were higher than 70 %. When neces-
sary, molecules were purified by RP-HPLC allowing purity
higher than 98 %. This new group of molecules was then
characterized in terms of the presence of secondary struc-
ture elements using circular dichroism (CD) as displayed in
Fig. 4. In a 30 % TFE solution, 4044 peptide and its
pseudopeptide analogs in both monomer and polymeric
forms exhibited a-helical features as judged by the pres-
ence of a maximal ellipticity at 190 nm and two minimal
ellipticity points at 208 and 222 nm, typical for this type of
secondary element, However, these molecules also had
more extended structural element features, such as
b-strands, highlighting the presence of a single minimum at
218 nm and unstructured regions. These molecules’
structural preference was thus intermediate, ranging from a
distorted helix to an unstable b-strand or can be randomly
organized. To confirm solution structure properties of this
molecular family, 1H-NMR experiments were conducted to
obtain representative molecular models as shown in Fig. 5
that will be discussed below.
Molecular structure calculation
In all cases, a set of 50 structures was obtained from the
native 4044 peptide’s coordinates as well as for its
pseudopeptides w-128 and w-130, satisfying experimental
constraints when 131 data NOEs-derived from distance
restraints which were previously classified according to
signal-strength. Then dihedral angles restraints were added
in molecular dynamics calculations for ensuring accuracy.
As expected due to a low number of medium-strength
NOE, signals for both peptide mimetics display a high
degree of flexibility in the whole pseudopeptide backbone.
The obtained molecular structures showed lower total
energy values.
Given the data’s relevance, 1H-NMR studies were then
made by applying two-dimensional techniques such as
nuclear Overhauser effect spectroscopy (NOESY) to gen-
erate more accurate data regarding the three molecules’ 3D
structure. 3D molecular models based on NMR data were
thus obtained for each molecule. The molecular structures
showed the stability of features displaying a-helix char-
acteristics; such features were seen to be stronger in native
peptide 4044 than in either peptidomimetic w-128 or
Fig. 4 Secondary structure profiles for all 4044-derived peptide
mimetics by circular dichroism (CD). In all cases the non-modified
peptide 4044 and its peptide mimetics were analyzed as both
monomer and polymer forms. Molar ellipticity is denoted by H whose
units are deg 9 cm2 9 dmol-1
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w-130. This was seen by the presence of several hydrogen
bonds which are usually displayed by helical structures.
The more relaxed structural trend in the two peptide
mimetics was also evident. The structural impact of the
two new degrees of freedom in both molecular analogs
was dramatic, in such a way that some characteristic
features from a-helices displayed by the native peptide
became lost in the new analogs, displaying more relaxed
conformations. Figure 5 displays the most representative
molecular models for 4044 peptide and its w-128 and
w-130 pseudopeptide analogs. Modification of specific
peptide bonds allowed new molecular constraints in the
global molecular structure which, as will be discussed,
will have a dramatic impact on their immunological
activity.
Hybridoma cloning and antibody isotype switching
and reactivity
Stable and highly specific antibodies directed against
MSA-2 were obtained after several steps involving limited
dilution cloning and sub-cloning of parent hybridomas
induced by both w-128 (31I–N32) and w-130 (30F–I31)
peptide mimetics, as described by the family tree displayed
in Fig. 6, left panel. Multiple cloning led to obtaining
homogeneous monoclonal antibodies expressing cells
which were letter-coded G, M, O and Q for those induced
by w-130 peptidomimetic and number-coded 6 and 7 for
those induced by the w-128 peptide mimetic (Fig. 6, right
panel). A group of hybridomas was generated; at first these
presented the IgM isotype. This pentavalent molecule
Fig. 5 The effect of introducing a single w–[CH2NH] peptide bond
modification on the MSA-221–40 fragment backbone and its relevance
to the molecule 3D structure. A consensus structure for peptide 4044
and its pseudopeptides w-128 and w-130, all having the lowest total
energy are displayed in ball and sticks representing the molecular 3D
structure of target molecules based on multidimensional 1H-NMR
experiments. The molecule backbone is shown by red ribbons.
Conformation properties for peptide MSA-221-40 (peptide 4044) in
panel (a) and its analog pseudopeptides w-128 in (b) and w-130 in (c).
Left panels show all molecules’ side view and right panels show the
molecules’ front view from the N- to C-terminus. Distance between
30F and 38S is shown in A˚. Left panels show all molecules’ side view
and right panels show the molecules’ front view from N- to
C-terminus
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served as the basis for carrying out in vitro immunization
assays to induce isotype switching to simpler, functional,
antibody forms. Table 2 shows the main results obtained
by this procedure and its versatility in inducing the drastic
change of IgM isotype to IgG1, IgG2a, IgG2b and IgG3
whose malaria infection neutralizing activity was evident
as will be discussed below. Given the importance of this
family of antibodies, Western blot experiments allowed to
analyze their cross-reactivity against an N-terminal MSA-2
recombinant fragment (rMSA-2). As observed in Fig. 7,
reactive clones induced by w-128 and w-130 revealed two
strong specific bands having relative molecular weights
ranging between 30.06 and 35.50 kDa, the slower being
recognized by an anti-histidine antibody. The rMSA-2
expressed fragment in an E. coli membrane lysate was
resolved on SDS-PAGE 10 % polyacrylamide gels and
electro-transferred to a nitrocellulose paper as discussed in
‘‘Materials and methods’’.
After successful clone and isotype characterization,
monoclonal antibodies induced by site-directed designed
peptide mimetics were tested for their reactivity against
native MSA-2 antigen from a Plasmodium falciparum
lysate resolved on a 7.5–15 % gradient gel by SDS-poly-
acrylamide gel electrophoresis. Western blot analysis for
specific antibody reactivity (Fig. 8) displayed reactivity
profiles for both sets of mAbs aw-128 and aw-130 anti-
bodies. The versatility of modifying adjacent residues
(involving two different residues, such as 30Phe-Ile31 and
31Ile-Asn32) induced two groups of antibodies having
strong, differential, specific reactivity; the first group
induced by w-130 (30Phe-Ile31) recognized a 37.90 kDa
band having relative mobility and the second group of
antibodies induced by w-128 (31Ile-Asn32) specifically
recognized two bands having 34.21 kDa and 30.54 kDa
relative molecular weights as displayed in Fig. 8a. An
important experiment allowed evidencing for the first time
the existence of a possible immature construct expressed
on the cytosol compartment of two rodent malaria species
such as Plasmodium berghei and Plasmodium yoelii
strains, as can be observed in Fig. 8b and c. In the cytosol
of P. berghei two strong bands were stained with mono-
clonal antibodies to the 4044-reduced pseudopeptides, a
slow band at 63.09 kDa and a faster one at 50.11 kDa.
Similarly in cytosol of P. yoelii two strong bands were also
Fig. 6 Genealogical tree of antibody clones induced by pseudopeptides w-128 and w-130 derived from the Plasmodium falciparum MSA-2
antigen so-called HABP 4044. Each level in the scale represents a sub-cloning of new antibody populations
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stained with monoclonal antibodies to the 4044-reduced
pseudopeptides, a slow band at 50.11 kDa and a faster one
at 44.46 kDa. In both cases, antibodies induced by the
w-128 exhibited a strong reactivity for the band having
higher relative molecular weight.
Mapping the MSA-221–40 epitope
The MSA-221–40 N-terminal-conserved sequence represented
by peptide 4044 (21KNESKYSNTFINNAYNMSIR40) pos-
sesses important functional features as described by different
authors. Firstly, the amino acid sequence 27SNTFINNA34
reported by Jones (Jones et al. 1996) represents an N-terminal
epitope; secondly, this protein fragment possesses a central
high binding motif to RBCs represented by the 30FIN32
amino acid sequence reported by Ocampo et al. (2000);
thirdly Patarroyo et al. (2011) have recently reported a
binding register to pockets 1–9 of the HLA-DRb1 constituted
by 30FINNAYNMS38 amino acid sequence, which after
being strategically modified by replacing specific amino
acids with others having physical and chemical characteris-
tics turned it into a protective immunogen that is considered
as a component for a sub-unit based malaria vaccine. How-
ever, the native 4044 molecule has proven to be poorly
immunogenic and non-protective against malaria when
administered as a non-modified sequence. Our experiments
have demonstrated that isostere bonds strategically located at
specific places within peptide sequences can be introduced as
novel important molecular elements for obtaining functional
immunogens as discussed below.
To precisely define the epitope present in the same
MSA-221–40 protein fragment, we propose using
Table 2 Isotype switching of clones induced by the w-128 and w-130 pseudopeptides derived from the MSA-221–40 peptide
























w-128 w-129 6 0.00 0.00 0.00 5.70 94.30 50 6.00 13.80 11.86 62.53 5.78
100 3.59 12.57 11.93 65.04 6.82
500 4.10 15.30 8.39 61.30 10.85
7 0.00 0.00 2.95 40.60 56.30 50 16.08 14.31 42.87 10.42 16.31
100 17.28 17.87 36.93 13.15 14.77
500 20.22 22.45 24.30 15.40 17.62
w-130 w-131 G 1.70 0.23 0.59 3.52 97.65 50 8.02 5.96 3.91 0.28 81.84
M 1.25 0.00 0.33 1.95 96.50
O 0.16 0.00 0.23 1.88 97.70 100 6.08 9.23 7.45 0.025 77.22
Q 0.00 0.00 0.18 5.30 94.50 500 3.52 2.39 1.81 0.00 92.28
Fig. 7 Reactivity of Aotus polyclonal antibodies and hybridoma-IgM
antibodies to MSA-2 peptide mimetics. a Antibody reactivity of
hybridoma-IgM produced antibodies induced by MSA-2 peptide
mimetics against a recombinant MSA-2 expressed in E. coli. Lane 1
for the negative control, lane 2 shows the reactivity of an anti-His
antibody, lanes 3 and 4 show the reactivity of IgM induced by w-130
and lanes 5 and 6 the reactivity of IgM induced by w-128. b Antibody
reactivity of Aotus monkeys immunized with MSA-2 peptide
mimetics against a recombinant MSA-2 expressed in E. coli; lane 1
the negative control, lane 2 the reactivity of an anti-His antibody, lane
3 the reactivity of polyclonal antibodies induced by w-130 in Aotus
monkeys, lane 4 the reactivity of polyclonal antibodies induced by w-
128 in Aotus monkeys, lanes 5 and 6 display the reactivity of pre-
immune sera from monkeys and lanes 7 and 8 sera reactivity of pre-
immune and post third dose samples of monkeys immunized with
native 4044 peptide
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monoclonal antibodies induced by the reduced amide
pseudopeptides each containing a non-natural peptide-bond
isostere, one located between the 30F–I31 amino acid pair on
the w-130 and the second between the 31I–N32 on the w-128
analog as molecular tools for mapping this protein fragment
epitope. The immunochemical tests performed evaluating
these mAbs cross-reactivity against a set of glycine scan
4044 peptide analogs are shown in Fig. 9a. As a result,
panels b and c of Fig. 9 display a recognition preference of
the central portion of the 4044 amino acid sequence. This
fact can be explained as: the antibody inducer pseudopep-
tides had included two new freedom degrees to the entire
molecule when the isostere –CH2–NH– was incorporated as
a –CO–NH– substituent. The effect on the molecule was
allowed by introducing two hydrogen atoms replacing an
oxygen atom in a given peptide bond. Thus, a replacement
of any amino acid in the central part of the molecule with a
glycine residue would resemble the two new freedom
degrees that both mAbs know how to recognize; in conse-
quence, a new epitope was revealed as the sequence
25KYSNTFIN32 at the N-terminal of the MSA-2 surface
antigen as can be observed in Fig. 9d.
Establishing in vitro and in vivo infection models
for rodent malaria
Bearing in mind the reactivity of this family of monoclonal
antibodies, we decided to perform in vivo experiments for
evaluating their possible functional activity in two infected
rodent malaria models. The characteristic morphology of
BALB/c mice erythrocytes infected with Plasmodium yo-
elii 17XL and Plasmodium berghei ANKA rodent malaria
strains allowed controlling and characterizing these two
entities’ erythrocyte cycle. Thus, different malarial parasite
blood stages, such as rings, trophozoites and mature
schizonts were produced in the blood stages of these
Fig. 8 Reactivity of IgG monoclonal antibodies generated by the
peptide mimetics w-128 and w-130 derived from native peptide 4044
by Western blot analysis. A The reactivity of monoclonal antibodies
induced by pseudopeptide w-130 can be observed at the left side of the
gel by the recognition of band (a) about a 37.9 kDa of relative
molecular weight and the reactivity of w-128-induced monoclonal
antibodies can be observed on the right by recognition of bands (b) and
(c) having relative molecular weights of 30.54 and 34.21 kDa,
respectively. B A cytosol protein extract obtained from Plasmodium
berghei was resolved by SDS-PAGE and electro-transferred to
nitrocellulose for analyzing the monoclonal antibody reactivity. C A
cytosol protein extract from Plasmodium yoelii was obtained as in the
previous case. In A a Plasmodium falciparum lysate (3 mg) electro-
phoresis was carried out on an acrylamide–bisacrylamide gel having
7.5–15 % gradient at 100 v for 4 h and then electro-transferred to
nitrocellulose paper and then cut into 0.5 cm strips. Each strip was
incubated with the corresponding antibody or as part of the control
group. In b and c, lane 1 is the negative control (i.e. blocking solution),
lanes 2 and 3 display the reactivity of monoclonal antibodies coded 6
and 7 induced by the pseudopeptide w-128 (31I–N32) and lanes 4–7
display the reactivity of monoclonal antibodies coded G, M, O and Q
induced by the pseudopeptide w-130 (30F–I31)
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Plasmodium strains. Each cell culture was maintained
under controlled conditions in stages lasting a month for
both cases. Preliminary studies for assessing in vitro anti-
plasmodium activity were conducted in controlled cultures
and showed a defined isotype antibody effect, which was
very similar to that observed in the in vivo antimalarial
activity assays. In all cases, parasitemia percentages were
lower than those in the control experiment, which was
normal infection of RBC parasitized with P. berghei after
two experimental challenges. The parasitemia peak
observed toward day 10 was due to the second in vitro
challenge. The P. yoelii strain was less virulent in in vivo
assays (as will be discussed further on). All groups
administered with antibodies had better control of parasi-
temia levels, except for the group treated with EGTA.
Once the infection models (in both in vitro controlled
cultures and in vivo BALB/c female mice) had been
established, the functional activity of monoclonal anti-
bodies induced by peptide mimetics derived from the
native peptide 4044 sequence was evaluated by using a
designed antibody passive administration scheme for P.
berghei- and P. yoelii-infected BALB/c mice. Thus, pas-
sive transference experiments were followed up over a
period of 40 and 30 days, respectively, as shown in Fig. 10.
Fig. 9 Mapping the N-terminal MSA-2 epitope. The peptide 4044
glycine scan analog peptides is displayed in a, b. The reactivity
pattern of monoclonal antibodies coded as G, M, O and Q induced by
the pseudopeptide w-130 (30F–I31) against the 4044 peptide glycine
scan. c. The reactivity pattern of monoclonal antibodies coded 6 and 7
induced by the pseudopeptide w-128 (31I–N32) against the 4044
peptide glycine scan. Each bar represents experiments performed in
duplicate by ELISA. d Schematic representation of the MSA-221–40
N-terminal region in which a redefined epitope is shown in (3), which
overlap the previously reported (1) (Jones et al. 1996) and a described
HLA-DRb1 reading frame motif (2) (Patarroyo et al. 2011)
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In all cases, the control groups (given (iv) isotonic saline
solution) presented higher infection kinetics than those
displayed by the study groups which were given pure
immunoglobulins having a defined isotype in the same
way. These groups also showed a delay in the emergence of
significant percentages of parasitemia and were able to
manage much higher parasitemia levels, showing that the
antibodies were having a modulating effect on the parasite.
Remarkably, the groups of animals which were given iso-
tonic saline solution became infected faster after experi-
mental challenge than the study groups, managing lower
parasitemia levels which were enough to cause the death of
the animals (this was not happening in the study groups).
The animals from the second group which were pas-
sively transferred with antibodies induced by w-128
(w-129) managed to significantly control infection,
reversing the P. berghei strain’s infectious effect. Animals
from groups 6 and 7, passively transferred with antibodies
induced by w-130 (w-131), managed to control infection
more efficiently compared to the other groups, showing the
potential effect of this peptidomimetic against the P.
berghei strain. The P. yoelii strain had virulence features
which were stronger that those displayed by P. berghei;
animals challenged with the former strain thus handled
higher parasitemia percentages. The effect of passively
transferred antibodies in mice managed to control infection
Fig. 10 Parasitemia patterns
for BALB/c mice passively
transferred with pseudopeptide
w -128 and w -130-induced
isotype-defined
immunoglobulins. a P. berghei-
infected BALB/c mice. b
P.-yoelii infected BALB/c mice.
Arrows display time mice were
challenged with rodent malaria
strains
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caused by P. yoelii in a similar way to that detected in the
first case (Fig. 10a, b). As in the first case, animals treated
with isotonic saline solution had lower parasitemia per-
centages, but died during a shorter period of time than the
remaining study groups. All groups studied were chal-
lenged twice, the first time by intravenous administration
and the second time intraperitoneally. Figure 11 displays
the percentage of animal survival after being Ig passively
administered.
Is should be stressed that all animals in the study groups
had 90–100 % protection during the first 20 days of the
in vivo assay during which the groups were experimentally
challenged with P. berghei, and the first 12 days after
experimental challenge of groups with P. yoelii. This is
why it was decided to induce fresh infection (reinfection)
intraperitoneally with twice the parasite load. As demon-
strated, treated animals were able to efficiently control
malaria infection until the passively administered antibody
had decreased its concentration; thus, boosting with the
same dose of immunoglobulin helped to maintain the
protective effect. Parasitemia percentages measured after
malaria in vivo infection of mice with Plasmodium berghei
and Plasmodium yoelii passively administered with specific
doses of monoclonal antibodies raised against site-directed
designed pseudopeptides were as follows: mice groups
administered mAbs against both w-128 and w-130
pseudopeptides and challenged with lethal doses of Plas-
modium berghei showed parasitemia levels of about
0–0.10 % until 20 days after the first i.v challenge with the
exception of groups 1 and 8. Group 1 was administered
isotonic saline solution and group 8 was transferred with
polyclonal antibodies against HPV virus-like particles,
with both groups displaying parasitemia levels closer to
10 % at day 5 (Fig. 10a, b). After a second i.p more lethal
challenging, parasitemia levels of all surviving animals
were effectively controlled in those antibody-administered






challenge was made with
a Plasmodium berghei and
b Plasmodium yoelii. In both
cases animals were distributed
in groups of five individuals as
shown in parenthesis. Group 1
was administered with isotonic
saline solution as being the




by the pseudopeptides w-128/
129 (I31–N32) and w-130/131
(30F–I31); in B animals were
administered with purified
monoclonal antibodies induced
by the pseudopeptide w-128/129
(I31–N32). Survival profiles
reveal the immunotherapeutical
effect of passively transferring
pure immunoglobulins into
rodent malaria-infected BALB/c
mice with lethal doses of
Plasmodium. All animals
administered with isotonic
saline solution died during the
experiment and numbers in
parentheses represent mice
codes
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animals, while animals belonging to control groups either
became rapidly infected or died after 4 days of the second
challenge.
Mice groups administered with mAbs against w-128
pseudopeptides and challenged with lethal doses of Plasmo-
dium yoelii showed parasitemia levels of about 0–0.15 %
until 15 days after the first i.v challenge with the exception of
group 1, which was administered isotonic saline solution,
displaying parasitemia levels closer to 5 % at day 5 (Fig. 10a,
b). As above, after a second i.p more lethal challenging,
parasitemia levels of all surviving animals were effectively
controlled in those antibody-administered animals, while
animals belonging to the control group became rapidly
infected or died after 3 days of the second challenge. As
experimentally observed, the Plasmodium yoelii strain was
more infective than the Plasmodium berghei strain.
On the other hand, isotype-defined immunoglobulins
possess neutralizing activity of the in vitro Plasmodium fal-
ciparum infection of human RBCs, in a dose-dependent
manner, since at a very low concentration these were efficient
invasion inhibitors as can be seen in Table 3 and discussed
below. This fact once more demonstrates the potential use of
these antibodies for controlling human malaria.
Discussion
Why a peptide bond should be modified in target
antigens
Nature-made amide bonds have a specific purpose, which
is to join two amino acids in a very simple but smart way.
Polypeptides are thus composed of amino acids covalently
bonded to each other like wagons on a train and so the
peptide bond is the ‘‘hook’’ that connects both building
blocks called amino acids. Such a molecular hook becomes
established once the carbonyl group belonging to the car-
boxylic primary function of a given amino acid is attacked
by an available electron pair belonging to the primary
amino function of another neighbor amino acid. Inside the
cells, peptide bonds are formed within ribosomes in a
controlled process called translation. Either, a natural
ribosomal or a solid-phase process that origins a newborn
peptide or protein is completed once a polypeptide chain
is assembled by bonding the genome coded twenty
N-a-amino-acids through peptide bonds.
This precise and well-designed molecular architecture
allows establishing many proteins as required by living
systems, always under a systematic genetical control.
However when the battle for survival between human
pathogens and their target cells are directed to given
molecules such as cell receptors, pathogens can use potent
and unique molecular mechanisms able to hydrolyzing
peptide bonds. Such molecular weapons are known as
peptidases, a kind of proteases having specific substrates
and thermodynamics for optimal activity. Thus, most
pathogens have adopted these molecular mechanisms for
either attacking human cells or destroying specific proteins
and antibiotics and so ensuring their survival. These are
only a couple of reasons why a peptide bond should be
substituted. On the other hand, our laboratory is working in
the hypothesis that parasitic human pathogens such as
Plasmodium falciparum employ molecular evasion mech-
anisms of the host immune system, based on modulating a
Table 3 In vitro invasion inhibition of Plasmodium falciparum to human RBC by antibodies against the w-130 (30F–I31) pseudopeptide
Sample Dilution Invasion % Invasion inhibition % ± SD
Controls RBCs 1 99 ± 0.012
Parasitized RBCs 100 0 ± 0.036
Chloroquine 1.85 mg/ml 01:27 18 82 ± 0.010
Chloroquine 0.93 mg/ml 01:54 14 80 ± 0.015
EGTA 1.9 mg/mL 31 69 ± 0.010
Ig pool (ionic strength) (mil) lg/ml Dilution Invasion % Invasion inhibition % ± SD
50 19.05 1/2 16 84 ± 0.046
1/4 82 18 ± 0.056
1/8 97 3 ± 0.012
100 56.92 1/2 81 19 ± 0.026
1/4 101 -1 ± 0.059
1/8 101 -1 ± 0.059
500 36.13 1/2 9 91 ± 0.021
1/4 18 82 ± 0.056
1/8 64 36 ± 0.047
932 J. M. Lozano et al.
123
specific 3D structure on its own proteins and activating
novel molecular pathways for invasion of red blood cells
(RBCs). This later possible evasion mechanism could be
blocked by mimicking those specific modulated 3D struc-
tures of parasite proteins by employing novel compounds
so-named peptide mimetics and pseudopeptides able to
induce site-directed antibodies having neutralizing prop-
erties of a malaria infection.
Two different specific peptide bond substitutions
in the same antigen lead to two well-defined peptide
mimetics
The site-directed design of peptide mimetics from amide-
reduced pseudopeptides using native sequence encoded
4044 (shown to be poorly immunogenic and non-pro-
tection inducing against malaria in previous studies and
the present one) led to obtaining two powerful pseudo-
peptides which were able to induce a humoral immune
response mediated by antibodies specifically recognizing
two groups of MSA-2 antigen-derived proteins. The
versatility of modifying peptide bonds between specific
adjacent residues (involving two different residues, such
as 30Phe-Ile31 and 31Ile-Asn32) when used as immuno-
gens have induced two groups of antibodies exhibiting
strong and specific reactivity; the first group induced by
w-130 (30Phe-Ile31) recognized a 37.90 kDa band having
relative mobility and the second group of antibodies
induced by w-128 (31Ile-Asn32) specifically recognized
two bands having 34.21 kDa and 30.54 kDa relative
molecular weights. These isotype-defined monoclonal
antibodies, derived from a hybridoma producing IgM
isotype immunoglobulins through in vitro immunization,
had neutralizing in vivo infection properties when pas-
sively transferred to BALB/c mice experimentally chal-
lenged with lethal doses of Plasmodium berghei and
Plasmodium yoelii, in a double-challenge administered
by two different routes. For the first time, we present
some evidence about the existence of MSA-2 protein
precursors or orthologous proteins present in the cytosol
of two rodent Plasmodium species, P. berghei and P.
yoelii. These antibodies allowed us to redefine the
N-terminal MSA-2 epitope as being the eight-residue
sequence 25KYSNTFIN32.
The well-defined molecular origin and background of
the obtained isotype-defined immunoglobulins’ in vitro
functional activity, demonstrated through infection assays
in controlled cultures as well as the evidence reported in
this study, led to proposing these reduced amide peptide
mimetics as potential components for inclusion in the
formulation of a sub-unit-based antimalarial vaccine and
their induced antibodies as potential immunotherapeutic
agents which could help to manage this disease.
A pathway toward immunotherapy in infectious
diseases
The site-directed design of peptide mimetics based on this
and previously reported Plasmodium surface antigens will
facilitate assessing the data reported in this study and
constitute new molecular tools to be applied in the clinical
management of malaria, as well as other transmissible
diseases. Fab/F(ab)2
0 immunoglobulin fragments or the
entire highly reactive antibody could be further employed
as a shock therapy in malaria endemic areas where infec-
tions could be controlled by intravenously administering
antibodies. As demonstrated in this work, mice have con-
trolled and resolved an experimental malaria infection after
being passively transferred with specific peptide-mimetic-
induced antibodies. On the other hand, in vitro antibody
isotype switching strategies can be successfully used to
ensure obtaining blocking neutralizing antibody in cell
culturing, then desirable isotype antibodies can be purified,
detoxified and properly formulated. In the present work
two important clue issues have to be taken into account:
first as proposed herein, a strategy for in vitro immuno-
globulin switching was successfully allowed by hybridoma
stimulation with a controlled dose of the antibody inducer
pseudopeptide; and secondly bearing in mind that such
isotype-defined antibodies were induced against specific
peptide-bond isostere surrogates designed in a site-directed
manner, this rationale could explain these antibody inhib-
itory effect on experimental malaria infection. As observed
in Table 3, isotype-defined immunoglobulins induced
against the w-130 pseudopeptide eluted at both 50 mM and
500 mM ionic strengths were able to inhibit Plasmodium
falciparum to human RBCs in a dose-dependent manner in
an average concentration of 40 lg/mL from 84 % ± 0.046
to 3 % ± 0.012 in the first case and from 91 % ± 0.021 to
36 % ± 0.047 in the second, evidencing a stronger inhib-
itory activity in the latter. Remarkably, immunoglobulins
eluted at a 100 mM ionic strength did not have an inhibi-
tory effect on the human in vitro malaria infection.
The analysis of the newly modified molecular structure,
in which an isostere peptide bond was introduced for
substituting a nature made one, secondary structure ele-
ments present in the native molecule are switched with
other elements able the molecule to reach energy states that
facilitate its interaction with antigen presenting molecules
of a HLA and TCR provoking a particular immune
response based on antibody production, these having spe-
cific neutralizing properties by using non-conventional
mechanisms for blocking parasites. Mimicking molecules
containing high energy with peptide mimetics such as
reduced amide pseudopeptides which possess four sp3
tetrahedral hybridized bonds replacing the three sp2 planar
of a normal peptide bond introduces new freedom degrees
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into the molecule and produces dramatic changes in the
entire molecular structure. Bearing in mind that structurally
modulated immunogens induces specific and site-directed
antibodies able to neutralize pathogens in a specific man-
ner, such compounds could be postulated to be new and
useful for novel malarial vaccine formulations.
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